2seventy bio (NASDAQ:TSVT) Earns “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 2seventy bio (NASDAQ:TSVT) in a research report released on Saturday morning,Weiss Ratings reports.

TSVT has been the topic of a number of other research reports. Leerink Partners reiterated a “market perform” rating and set a $5.00 price objective (down previously from $9.00) on shares of 2seventy bio in a research note on Tuesday, March 11th. Leerink Partnrs cut 2seventy bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 11th. Finally, Morgan Stanley dropped their price objective on 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $6.67.

2seventy bio Trading Up 0.2 %

2seventy bio stock opened at $4.96 on Friday. 2seventy bio has a 52 week low of $2.29 and a 52 week high of $5.99. The stock has a market cap of $255.88 million, a price-to-earnings ratio of -2.67 and a beta of 1.73. The company’s 50-day moving average price is $3.04 and its two-hundred day moving average price is $3.70.

Insider Buying and Selling at 2seventy bio

In other 2seventy bio news, major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $4.93, for a total transaction of $25,350,607.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William D. Baird III sold 5,092 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $4.95, for a total transaction of $25,205.40. Following the completion of the transaction, the chief executive officer now owns 1,121,034 shares of the company’s stock, valued at approximately $5,549,118.30. The trade was a 0.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,152,093 shares of company stock valued at $25,400,018. Corporate insiders own 7.20% of the company’s stock.

Institutional Investors Weigh In On 2seventy bio

A number of large investors have recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new position in 2seventy bio in the 3rd quarter worth approximately $64,000. Intech Investment Management LLC acquired a new stake in shares of 2seventy bio in the third quarter worth $69,000. FMR LLC grew its holdings in shares of 2seventy bio by 22.0% during the third quarter. FMR LLC now owns 148,545 shares of the company’s stock valued at $701,000 after buying an additional 26,738 shares in the last quarter. BBR Partners LLC grew its holdings in shares of 2seventy bio by 620.0% during the third quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock valued at $850,000 after buying an additional 155,000 shares in the last quarter. Finally, PDT Partners LLC acquired a new position in 2seventy bio during the third quarter valued at $244,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.